絞り込み

16426

広告

「vonoprazan」の検索結果

119件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors.

Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis.

Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study.

Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.

Update on use of vonoprazan: a competitive acid blocker (P-CAB).

Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers.

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

Eosinophilic esophagitis in Japan - Focus on response to acid suppressive therapy.

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.

Risk Factors for Delayed Ulcer Healing after Endoscopic Submucosal Dissection of Gastric Neoplasms.

Immune thrombocytopenia induced by vonoprazan fumarate: a single center retrospective study.

Parietal Cell Protrusions and Dilated Oxyntic Glands from Use of Vonoprazan.

Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis.

Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.

First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin.

Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility.

Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.

Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
Sort by
※並べ替えは表示に時間がかかります